Figure 7

Chronic morphine-induced EPSC augmentation involves the protein kinase C pathway. A, Representative EPSCs in the absence and presence of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA, 1 μM) in a saline control cell and a tolerant cell. B, PMA effect on the peak amplitude of eEPSCs in saline control and tolerance cells. C,D, Representative EPSC pairs (C) and the same pairs after normalization (D) in tolerant cells with or without treatment with the PKC inhibitor GF109203X. E, Group data of the GF109203X effect on PPR in tolerant (n = 8) and saline control cells (n = 6).